Td Asset Management Inc Intercept Pharmaceuticals, Inc. Transaction History

Td Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 10, 2020	SELL	$39.09 - $53.44 $423,618 - $579,129	-10,837 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$46.7 - $92.04 $186,800 - $368,160	-4,000 Reduced 26.96%	10,837 $519,000
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $62,855 - $154,284	-1,300 Reduced 8.06%	14,837 $934,000
Q4 2019 Feb 11, 2020	BUY	$57.36 - $124.1 $430,200 - $930,750	7,500 Added 86.84%	16,137 $2 Million
Q3 2019 Nov 07, 2019	SELL	$58.69 - $80.46 $52,821 - $72,414	-900 Reduced 9.44%	8,637 $573,000
Q2 2019 Aug 01, 2019	BUY	$77.77 - $120.68 $26,208 - $40,669	337 Added 3.66%	9,537 $759,000
Q1 2019 May 08, 2019	BUY	$91.83 - $120.68 $844,836 - $1.11 Million	9,200 New	9,200 $1.03 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.